Q-linea AB (publ) (STO: QLINEA)

Market Cap	440.48M
Revenue (ttm)	7.13M
Net Income (ttm)	-224.61M
Shares Out	116.84M
EPS (ttm)	-2.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,744
Open	3.890
Previous Close	3.770
Day's Range	3.700 - 3.950
52-Week Range	1.950 - 5.600
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Q-linea AB

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. The company offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. It serves healthcare providers. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Employees: 127
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLINEA

Financial Performance

In 2023, Mendus AB's revenue was 28.49 million, an increase of 851.15% compared to the previous year's 3.00 million. Losses were -101.62 million, -26.78% less than in 2022.